Instrument Inactif

Communiqués EKIMAS Corporation Other OTC

Actions

ASNB

US28265K1060

Communiqués

15/06	Nordicus Partners Corporation Corporate Update	AQ
06/02	Nordicus Partners Corporation Corporate Update	AQ
13/11	NoviThera has initiated the first efficacy animal studies	AQ
22/10/25	Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.	AQ
20/10/25	Orocidin develops novel cGMP manufacturing process in collaboration with Syngene	AQ
03/10/25	Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS	AQ
02/09/25	Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market	AQ
07/08/25	Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors	AQ
03/04/25	Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia	AQ
02/04/25	Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in Dogs	AQ
13/11/24	Nordicus Partners : Acquires the Remaining 5% Shares In Orocidin A/S Form 8 K	PU
13/11/24	Nordicus Partners : Acquires Bio Convert ApS Form 8 K	PU
11/11/24	Nordicus Partners Corporation Acquires Bio-Convert ApS	AQ
07/11/24	Nordicus Partners Corporation Announces Reverse Stock Split	AQ
03/07/24	Nordicus Partners To Host Investor Relations Webinar on July 10, 2024	AQ
21/06/24	Nordicus Partners Corporation Enters Into A Consultancy Agreement With BIO-CONVERT In Denmark	AQ
11/06/24	Orocidin – New Insights Into The Treatment Of Periodontitis	AQ
04/06/24	Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of Directors	AQ
23/05/24	Nordicus Partners Corporation Engages FORCE Family Office	AQ
15/05/24	Nordicus Partners Corporation Acquires 95% Stake in Orocidin A/S	AQ
09/05/24	Nordicus Partners Corporation Uplists to OTCQB	AQ
10/01/24	NORDICUS PARTNERS CORPORATION ENTERS INTO A CONSULTANCY AGREEMENT WITH OROCIDIN A/S IN DENMARK	AQ
03/05/23	EKIMAS CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
08/03/23	EKIMAS CORPORATION COMPLETES THE EXERCISE OF WARRANTS	AQ
01/03/23	EKIMAS CORP : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Changes in Control or Registrant, Change in Directors or Principal Officers, Change in Shell Company Status, Other Events, Financial Statements and Exhibits (form 8-K)	AQ